Why Is HALOZYME THERAPEUTIC (HALO) Stock Up Today?

Halozyme Therapeutics shares climbed 7.48% to close at $117.82 on Wednesday. The primary driver was a significant price target increase from TD Cowen, which lifted its outlook to $130 from $105. This move followed an FDA approval that prompted H.C. Wainwright to reiterate its rating on the stock.

What Happened

TD Cowen raised its price target on Halozyme to $130 while maintaining a Buy rating. The firm cited the company's recent FDA approval as a key catalyst for the upward revision. H.C. Wainwright also reiterated its rating on the stock following the same regulatory milestone. These analyst actions provided fresh momentum to a stock that had been trading in a narrow range recently. The company’s market capitalization now stands at $12.6 billion.

What The Data Shows

The stock printed 34 fresh 52-week highs on October 14, 2026, signaling strong recent momentum. The 52-week range spans from $61.23 to $116.84, placing the current price near the upper end of that interval. Fundamentals show a P/E ratio of 32.4, with trailing twelve-month revenue growth of 41.2% and a net margin of 24.9%. The beta is 0.88, indicating lower volatility relative to the broader market. Intraday, the stock opened at $109.93 and hit a session high of $118.45 at 11:35 AM ET. Volume was 1.2 million shares, which is 0.6 times the three-month daily average. Over the last 8 sessions, the stock moved up 0.5%, from $109.11 to $109.62. Recent insider activity includes six sells totaling $22.1 million over the last 90 days, with no buys. CEO Torley Helen sold shares on October 6, 2026, and Director Matthew L. Posard sold on October 1 and September 16, 2026.

What To Watch

Investors will monitor how the stock sustains its position near the 52-week high following the analyst upgrades. The recent surge in 52-week highs suggests continued interest, but the lower-than-average volume may indicate a need for further participation to confirm the trend.